Antibody response linked with rejection in pediatric kidney transplant recipients

A transplanted kidney has a finite life expectancy because it often becomes the target of the recipient's immune system, which may mount antibodies that attack the organ. Because there is a critical need to extend the life of transplanted organs—especially in children, who can face two to three kidney transplants in their lifetime—researchers recently examined the role of this antibody-mediated injury in rejection and the effectiveness of medications to prevent it. Their findings are reported in the Journal of the American Society of Nephrology (JASN).

Minnie Sarwal, MD, FRCP, PhD (California Pacific Medical Center) and her colleagues mapped the antibody in 130 children who received kidney transplants through 12 different US transplant programs participating in a trial comparing complete steroid avoidance after transplantation and standard steroid therapy after transplantation. (Some patients received long-term steroids after transplantation as a treatment to potentially protect the new organ from antibody-mediated injury, while others received no steroids.) Patients were monitored for two years after transplantation.

"The development of antibodies were confirmed to injure the transplant, though the incidence of this antibody-mediated injury to the transplant was quite low at only about 6%," said Dr. Sarwal. Patients with these antibodies were more likely to experience organ injury and rejection than patients without these antibodies.

Also, steroids did not seem to provide a benefit. "There was no difference in the immune response in children who did not receive steroids, though there was a huge benefit in their growth, in lower blood pressures, and levels, supporting the importance of avoiding steroids in children after transplantation wherever possible," she added.

The researchers recommend monitoring recipients for the presence of antibodies directed against transplanted organs at various stages and customizing immunosuppressive treatments to prevent rejection.

More information: The article, entitled "Humoral Immunity Associates with Outcomes in Pediatric Renal Transplantation," will appear online on February 28, 2013, doi: 10.1681/ASN.2012070663

add to favorites email to friend print save as pdf

Related Stories

Promising breakthrough for transplant patients

Feb 27, 2013

A team led by Dr. Marie-Josée Hébert from the University of Montreal Hospital Research Centre (CRCHUM) has discovered a new cause of organ rejection in some kidney transplant patients. Her team has identified a new class ...

Time to stop giving toxic drugs to kidney transplant patients?

Sep 22, 2011

Patients who receive kidney transplants must take lifelong medications that, while preventing organ rejection, can also compromise other aspects of health. Immunosuppresive drugs called calcineurin inhibitors protect transplanted ...

Recommended for you

Schumacher's doctor sees progress after injury

10 hours ago

A French physician who treated Michael Schumacher for nearly six months after the Formula One champion struck his head in a ski accident says he is no longer in a coma and predicted a possible recovery within three years.

New MCAT shifts focus, will include humanities

Oct 20, 2014

(HealthDay)—The Medical College Admission Test (MCAT) has been revised, and the latest changes, including more humanities such as social sciences, are due to be implemented next April, according to a report ...

User comments